Biotech Values

[jbog]

Turtle,

Back in July I thought Marth was quoted as saying that T-Enox was a month away from being approved. What happened Bill?

Now if we approach January and there is no T-Enox are the analysts going to just accept whatever position Teva puts out there?

As far as both Teva's and Momenta's future goes I see more damage coming from Novartis's Gilenya which possibly could do substaintial damage to the Copaxone franchise in the end run.

There is only one thing that bothers me at this point, and that's the departure of Sasisekharan and Brugger.